News

Published on 20 Jun 2024 on GuruFocus.com · via Yahoo Finance

Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX)

Article preview image

On June 20, 2024, Houte Van, Chief Financial Officer of Nurix Therapeutics Inc (NASDAQ:NRIX), executed a sale of 20,000 shares of the company at a price of $20.01 per share. This transaction was documented in an SEC Filing. Following this sale, the insider now owns 48,333 shares of Nurix Therapeutics Inc.

Warning! GuruFocus has detected 8 Warning Signs with NRIX.

Read the rest of the article
NASDAQ.NRIX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Why Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks...

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential Accord...

Insider Monkey · via Yahoo Finance 4 Dec 2024
Cathie Wood's Latest Shake-up: Dumps Palantir And Jack Dorsey's Block Along With...

On Monday, Cathie Wood-led Ark Invest made significant trades, with the most notable being the tr...

Benzinga 5 Nov 2024
Nurix therapeutics CFO Hans van Houte sells $57,554 in stock By Investing.com

SAN FRANCISCO—Hans van Houte, Chief Financial Officer of Nurix Therapeutics, Inc. (NASDAQ:NRIX),...

Investing.com 31 Oct 2024
Nurix therapeutics chief legal officer sells shares worth over $101k By...

SAN FRANCISCO—Christine Ring, Chief Legal Officer at Nurix Therapeutics, Inc. (NASDAQ:NRIX),...

Investing.com 31 Oct 2024
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a favorite amongst institutional...

Key Insights Significantly high institutional ownership implies Nurix Therapeutics' stock price i...

Simply Wall St. · via Yahoo Finance 20 Jun 2024
Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX)

On June 20, 2024, Houte Van, Chief Financial Officer of Nurix Therapeutics Inc (NASDAQ:NRIX), exe...

GuruFocus.com · via Yahoo Finance 20 Jun 2024
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study

Roche Holding AG RHHBY announced that the late-stage study evaluating its marketed drug, Columvi ...

Zacks via Yahoo Finance 15 Apr 2024
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering By Investing.com

Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten...

Investing.com 12 Apr 2024
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

Nurix Therapeutics, Inc. ( Nasdaq : NRIX) today announced the pricing of its upsized underwritten...

Investing.com 12 Apr 2024
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study

ALX Oncology Holdings Inc. ALXO reported positive results from an ongoing phase I/II investigator...

Zacks via Yahoo Finance 11 Apr 2024

Copyright Statfolio @ 2025

Social Accounts